Fol. Biol. 2012, 58, 1-6
https://doi.org/10.14712/fb2012058010001
Molecularly-Targeted and Biological Anti-Cancer Therapy
References
1. , W., Ivanov, A., Honeychurch, J., Cheadle, E. J., Potluri, S., Lim, S. H., Shimada, K., Chan, C. H., Tutt, A., Beers, S. A., Glennie, M. J., Cragg, M. S., Illidge, T. M. (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117, 4519-4529.
<https://doi.org/10.1182/blood-2010-07-296913>
2. , G., Watier, H., Golay, J., Solal-Celigny, P. (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104, 2635-2642.
<https://doi.org/10.1182/blood-2004-03-1110>
3. , B. J. (2002) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31-36.
<https://doi.org/10.1016/S1535-6108(02)00025-9>
4. , B. J. (2004) Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1-30.
<https://doi.org/10.1016/S0065-230X(04)91001-9>
5. European Medicines Agency (2011) Concept paper on the revision of the guideline on similar biological medicinal product. ref. no. eMA/CHMP/BMWP/572643/2011.
6. , M. A., Collins, F. S. (2010) The path to personalized medicine. N. Engl. J. Med. 363, 301-304.
<https://doi.org/10.1056/NEJMp1006304>
7. , A., Hazleman, B. L., Ostor, A. J. (2007) Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad. Med. J. 83, 251-260.
<https://doi.org/10.1136/pgmj.2006.052688>
8. , H. (2007) Biotechs go generic: the same but different. Nature 449, 274-276.
<https://doi.org/10.1038/449274a>
9. , G., Lammens, A., Mundigl, O., Georges, G. J., Schaefer, W., Schwaiger, M., Franke, A., Wiechmann, K., Jenewein, S., Slootstra, J. W., Timmerman, P., Brannstrom, A., Lindstrom, F., Mossner, E., Umana, P., Hopfner, K. P., Klein, C. (2011) epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 118, 358-367.
<https://doi.org/10.1182/blood-2010-09-305847>
10. , M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E., Raab, R., Newman, R. A., Hanna, N., Anderson, D. R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445.
<https://doi.org/10.1182/blood.V83.2.435.435>
11. , T., Robak, E. (2011) New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. 25, 13-25.
<https://doi.org/10.2165/11539590-000000000-00000>
12. , M., Stangler, T., Torella, C., Cepeljnik, T., Toll, H., Grau, R. (2011) Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat. Biotechnol. 29, 310-312.
<https://doi.org/10.1038/nbt.1839>
13. , M., Bielsky, M. C., De Smet, K., Ehmann, F., Ekman, N., Narayanan, G., Heim, H. K., Heinonen, E., Ho, K., Thorpe, R., Vleminckx, C., Wadhwa, M., Schneider, C. K. (2011) Biosimilars – why terminology matters. Nat. Biotechnol. 29, 690-693.
<https://doi.org/10.1038/nbt.1936>
14. , A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., Forero-Torres, A. (2010) Brentuximab vedotin (SGn-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812-1821.
<https://doi.org/10.1056/NEJMoa1002965>
